Riskpilot← Back to searchSign inGet full accessBrommatandläkarna AB
ABDissolvedOrg 5567043525Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 200610 employees
Revenue 2023
SEK 14,6M
+21% vs 2022
EBITDA margin
23.9%
+19% vs 2022
Equity ratio
44.0%
Financial strength
Net profit 2023
SEK 1,8M
-7% vs 2022
| Revenue | SEK 14,6M | +21% |
| EBITDA | SEK 3,5M | +19% |
| Net profit | SEK 1,8M | -7% |
| Total assets | SEK 8,6M | -7% |
| Equity | SEK 3,8M | +19% |
| Employees | 10 | — |
Legal name
Brommatandläkarna AB
Org number
5567043525
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
18 maj 2006
Share capital
SEK 100 000
Employees
10 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva tandläkarverksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 9 251 | 8 538 | 9 505 | 12 116 | 14 644 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 975 | 1 755 | 2 133 | 2 947 | 3 504 |
| Depreciation & amort. | −154 | −156 | −144 | −191 | −277 |
| EBIT | 1 821 | 1 599 | 1 989 | 2 756 | 3 227 |
| Net financials | −57 | −49 | −49 | −67 | −85 |
| Profit before tax | 1 934 | 1 160 | 1 452 | 2 527 | 2 329 |
| Tax | −433 | −255 | −316 | −534 | −482 |
| Net profit | 1 501 | 905 | 1 136 | 1 993 | 1 847 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 4 438 | 4 549 | 6 103 | 9 200 | 8 589 |
| Equity | 1 601 | 1 306 | 2 443 | 3 186 | 3 783 |
| Long-term debt | 1 625 | 1 625 | 1 625 | 3 625 | 1 625 |
| Short-term debt | 889 | 905 | 835 | 1 027 | 1 008 |
| Total debt | 2 514 | 2 530 | 2 460 | 4 652 | 2 633 |
EBITDA margin
23.9%
This company
15.8%
Market median
+51% vs market
20192023
Equity ratio
44.0%
This company
38.2%
Market median
+15% vs market
20192023
Return on equity
48.8%
This company
18.4%
Market median
+165% vs market
20192023
Net profit margin
12.6%
This company
8.1%
Market median
+56% vs market
20192023
Asset turnover
1.70×
This company
1.12×
Market median
+52% vs market
20192023
Debt / equity
1.27×
This company
0.62×
Market median
-105% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SW Chief Auditor | Chief Auditor | 2024 |
MB Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (2) | ||
RH Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
IM | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Brommatandläkarna AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ragnhild Hulda Margareta Hansson | Chief Executive Officer | 0 companies |
| Susanne Westman | Chief Auditor | 0 companies |
| Irma Margaretha Morén | Audit | 0 companies |
| Malin Birgitta Schmidt | Chief Executive Officer | 0 companies |
| Per Anders Yngve Hansson | Deputy Board Member | 0 companies |
| Karl Fredric Danielsson | Deputy Board Member | 0 companies |